Mycophenolate mofetil
- PMID: 17970888
- DOI: 10.1111/j.1529-8019.2007.00136.x
Mycophenolate mofetil
Abstract
Mycophenolate mofetil (MMF) is a relatively new systemic immunosuppressive agent whose use is rapidly increasing within the field of dermatologic. Originally used in the 1970s for the treatment of psoriasis, MMF has demonstrated efficacy in multiple types of inflammatory skin diseases. Although the safety data within the dermatologic literature is sparse, MMF's extensive use within the field of organ transplantation has demonstrated a favorable safety profile. MMF's lack of hepatic or renal toxicity is a significant advantage over immunosuppressive medications currently used in dermatology and make MMF an attractive candidate for multidrug regimens. In this review the present authors discuss the pharmacology, mechanisms of action, side effects and current uses of MMF reported within the dermatologic literature. The present authors also provide practical information regarding the use of the MMF culled from the literature as well as from the present authors' own clinical experience with the medication.
Similar articles
-
Mycophenolic acid in dermatology a century after its discovery.Australas J Dermatol. 2015 Feb;56(1):77-83. doi: 10.1111/ajd.12259. Epub 2014 Dec 30. Australas J Dermatol. 2015. PMID: 25557632 Review.
-
Mycophenolate mofetil in dermatology.J Am Acad Dermatol. 2009 Feb;60(2):183-99; quiz 200-2. doi: 10.1016/j.jaad.2008.08.049. J Am Acad Dermatol. 2009. PMID: 19150270 Review.
-
Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses.J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):445-9. doi: 10.1016/s0190-9622(97)70147-6. J Am Acad Dermatol. 1997. PMID: 9308561 Review.
-
[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].Hautarzt. 2000 Feb;51(2):63-9. doi: 10.1007/s001050050013. Hautarzt. 2000. PMID: 10743574 Review. German.
-
Mycophenolate mofetil: a dermatologic perspective.Skin Therapy Lett. 2005 Apr;10(3):1-6. Skin Therapy Lett. 2005. PMID: 15986076
Cited by
-
Use of Systemic Mycophenolate Mofetil Therapy in Ocular Surface Inflammatory Pathologies at the Initiative and Responsibility of the Ophthalmologist.Middle East Afr J Ophthalmol. 2023 Nov 21;29(4):209-215. doi: 10.4103/meajo.meajo_109_23. eCollection 2022 Oct-Dec. Middle East Afr J Ophthalmol. 2023. PMID: 38162558 Free PMC article.
-
Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis.Rheumatol Ther. 2024 Feb;11(1):113-127. doi: 10.1007/s40744-023-00623-4. Epub 2023 Nov 25. Rheumatol Ther. 2024. PMID: 38001304 Free PMC article.
-
Case report: One pediatric liver-transplant recipient with SARS-CoV-2 infection suffering unexplained mixed acidosis.Front Med (Lausanne). 2023 Jan 4;9:972978. doi: 10.3389/fmed.2022.972978. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36687457 Free PMC article.
-
Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States.Rheumatol Ther. 2023 Oct;10(5):1305-1318. doi: 10.1007/s40744-023-00577-7. Epub 2023 Jul 21. Rheumatol Ther. 2023. PMID: 37477809 Free PMC article.
-
Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report.Front Med (Lausanne). 2022 Apr 12;8:811562. doi: 10.3389/fmed.2021.811562. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35495200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical